CLINICAL_TRIALS
trial_result
· 2026-02-04
Clinical Trial Update: A Phase III Study of GS101 Injection to Dupixent® [Phase 3]
Summary
A Phase 3 clinical trial evaluating GS101 Injection in combination with Dupixent for atopic dermatitis is not yet recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd | Conditions: Atopic Dermatitis (AD) | Phase 3 | Status: NOT_YET_RECRUITING